Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Non-Current Deffered Revenue: 2024-2025

Historic Non-Current Deffered Revenue for Gossamer Bio (GOSS) over the last 2 years, with Sep 2025 value amounting to $27.1 million.

  • Gossamer Bio's Non-Current Deffered Revenue fell 38.13% to $27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.1 million, marking a year-over-year decrease of 38.13%. This contributed to the annual value of $38.9 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Gossamer Bio's Non-Current Deffered Revenue stood at $27.1 million, which was down 13.97% from $31.5 million recorded in Q2 2025.
  • Gossamer Bio's Non-Current Deffered Revenue's 5-year high stood at $49.7 million during Q2 2024, with a 5-year trough of $27.1 million in Q3 2025.
  • Its 2-year average for Non-Current Deffered Revenue is $37.9 million, with a median of $37.8 million in 2024.
  • Data for Gossamer Bio's Non-Current Deffered Revenue shows a maximum YoY tumbled of 38.13% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Gossamer Bio's Non-Current Deffered Revenue stood at $38.9 million in 2024, then slumped by 38.13% to $27.1 million in 2025.
  • Its last three reported values are $27.1 million in Q3 2025, $31.5 million for Q2 2025, and $36.7 million during Q1 2025.